Meridian Bioscience — Q2 FY2021 Earnings Presentation
9 slides from Meridian Bioscience's earnings presentation, May 7, 2021
Slide 1: FY2021 Q2 Results
FY2021 Q2 Results May 7, 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A
Slide 3: Non-GAAP Financial Measures
Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and net earnings per diluted share, each on an adjusted basis, excluding as applicable the effects of acquisition-related costs, changes in fair value of acquisitio
Slide 4: Q2 FY2021 Business Highlights
Signed agreement for 2nd RADx grant - $5.5M for ramping manufacturing of Revogene® SARS-CoV-2 Assay Submitted 510(k) for Curian ® Campy assay Launched first Air-Dryable sample specific Master Mix for Blood Q2 FY2021 Business Highlights Diagnostics Life Science
Slide 5: Second Quarter Earnings Summary
FY2021 Second Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2021 FY2020 Change Net revenues $85,264 $57,296 +49% Gross margin % 68% 60% +8 pts Operating expenses(1) Ratio $25,530 30% $22,472 39% +14% -9 pts Operating income Margin % $32,242 38% $12,074 21% +167% +1
Slide 6: Second Quarter Operating Segment Highlights
FY2021 Second Quarter Operating Segment Highlights ($000’s) Diagnostics segment (Adjusted Non-GAAP) FY2021 FY2020 Change Net revenues $31,949 $34,942 -9% Operating income / (loss) Margin % ($568) NMF $4,224 12% NMF NMF Diagnostics segment revenue by: Technology: Molecular assays $4,395 $7,238 -39% N
Slide 7: Fiscal Year Guidance
FY2021 Fiscal Year Guidance Meridian Bioscience Diagnostics Life Science Prior Guidance (2/5/2021) Updated FY2021 Guidance Meridian Bioscience Consolidated net revenues: $305 to $335 Million Adjusted operating margin: 30% to 33% Adjusted net earnings per share*: $1.60 to $1.80 Diagnostics Net revenu
Slide 8: The Curian Campy Advantage
Fluorescent analyzer Improved performance with no subjectivity Intuitive user interface Intuitive, fast, and easy-to-use improves productivity Simple sample prep Clean, comfortable handling of samples Easy, standardized workflow Implement & train only once The Curian® Campy Advantage
Slide 9: Contact
Contact: mbi@meridianbioscience.com
Meridian Bioscience — Q2 FY2021 Earnings Presentation on 6ix